Pfizer Inc. (PFE): Price and Financial Metrics

Pfizer Inc. (PFE): $40.66

-0.15 (-0.37%)

POWR Rating

Component Grades














  • Value is the dimension where PFE ranks best; there it ranks ahead of 96.79% of US stocks.
  • PFE's strongest trending metric is Stability; it's been moving down over the last 178 days.
  • PFE ranks lowest in Momentum; there it ranks in the 9th percentile.

PFE Stock Summary

  • PFE has a market capitalization of $225,324,892,302 -- more than approximately 99.38% of US stocks.
  • PFIZER INC's stock had its IPO on January 1, 1986, making it an older stock than 93.42% of US equities in our set.
  • PFE's current price/earnings ratio is 7.18, which is higher than only 20.54% of US stocks with positive earnings.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PFIZER INC are NVS, AZN, CSCO, BMY, and NFLX.
  • Visit PFE's SEC page to see the company's official filings. To visit the company's web site, go to

PFE Valuation Summary

  • In comparison to the median Healthcare stock, PFE's EV/EBIT ratio is 14.5% higher, now standing at 7.5.
  • Over the past 243 months, PFE's price/earnings ratio has gone down 15.

Below are key valuation metrics over time for PFE.

Stock Date P/S P/B P/E EV/EBIT
PFE 2023-03-17 2.2 2.4 7.2 7.5
PFE 2023-03-16 2.3 2.4 7.2 7.6
PFE 2023-03-15 2.3 2.4 7.2 7.5
PFE 2023-03-14 2.2 2.3 7.1 7.5
PFE 2023-03-13 2.2 2.3 7.1 7.5
PFE 2023-03-10 2.2 2.3 7.1 7.4

PFE Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at -11.47%.
  • The 3 year revenue growth rate now stands at 71.5%.
  • Its 5 year cash and equivalents growth rate is now at -46.98%.
Over the past 49 months, PFE's revenue has gone up $46,303,000,000.

The table below shows PFE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 99,676 26,599 29,771
2022-06-30 101,132 31,454 29,309
2022-03-31 92,367 34,583 24,966
2021-12-31 81,288 32,580 21,979
2021-09-30 63,600 32,291 19,180
2021-06-30 51,637 23,552 13,228

PFE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PFE has a Quality Grade of B, ranking ahead of 88% of graded US stocks.
  • PFE's asset turnover comes in at 0.312 -- ranking 146th of 682 Pharmaceutical Products stocks.
  • XBIT, NERV, and BLUE are the stocks whose asset turnover ratios are most correlated with PFE.

The table below shows PFE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-04 0.312 0.704 0.149
2021-04-04 0.265 0.763 0.116
2020-12-31 0.247 0.793 0.099
2020-09-27 0.282 0.799 0.083
2020-06-28 0.288 0.799 0.181
2020-03-29 0.307 0.799 0.200

PFE Price Target

For more insight on analysts targets of PFE, see our PFE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $46.03 Average Broker Recommendation 1.8 (Hold)

PFE Stock Price Chart Interactive Chart >

Price chart for PFE

PFE Price/Volume Stats

Current price $40.66 52-week high $56.32
Prev. close $40.81 52-week low $39.23
Day low $40.31 Volume 19,981,900
Day high $40.91 Avg. volume 24,017,650
50-day MA $43.07 Dividend yield 4.09%
200-day MA $47.22 Market Cap 229.50B

Pfizer Inc. (PFE) Company Bio

Pfizer Inc. is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products. Pfizer was founded under its original name, Charles Pfizer & Company, in 1849 in Brooklyn, New York by Charles Pfizer and Charles Erhart. The company operates research and development facilities in United States and the United Kingdom and employs over 78,000 individuals worldwide. Some of the company’s more recognizable brands include Advil, Celebrex, Chantix, Chapstick, Dimetapp, Lipitor, Robitussin, and Viagra. Albert Bourla serves as Pfizer’s Chairman of the Board and Chief Executive Officer and the company is headquartered in New York, New York.

PFE Latest News Stream

Event/Time News Detail
Loading, please wait...

PFE Latest Social Stream

Loading social stream, please wait...

View Full PFE Social Stream

Latest PFE News From Around the Web

Below are the latest news stories about PFIZER INC that investors may wish to consider to help them evaluate PFE as an investment opportunity.

Pfizer CEO pockets $33M for 2022 after 36% pay hike

Pfizer (NYSE:PFE) Chief Executive and Chairman Albert Bourla will likely become one of the top-earning pharma CEOs for 2022 after the pharma giant took his total compensation to $33.0M handing him a ~36% pay hike for last year.

Meanwhile, Johnson & Johnson (JNJ), whose former helmsman Alex Gorsky was the highest-paid pharma CEO in 2021, rewarded its new CEO Joaquin Duato, with a $13.1M package, indicating a ~51% decline in the Seeking Alpha | March 19, 2023

Easing COVID pandemic sees many pharmas seeking alternate revenue streams

Although the COVID-19 pandemic ended up being a cash cow for several pharma and biotech companies, many of them are seeking other treatments to focus on to replace revenue that is beginning to fade away.

With their mRNA vaccines, Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), and BioNTech (BNTX) were amo...

Seeking Alpha | March 19, 2023

7 Stocks Set to Soar When the Market Recovers

Although investors are freaking out over the banking sector fallout, bold contrarians may consider these stocks to buy.

Josh Enomoto on InvestorPlace | March 17, 2023

7 High-Yield Dividend Stocks That Can Double Your Money in 2023

These are the high-yield dividend stocks to buy for 100% total returns in 2023 in anticipation of a rally from deeply oversold levels.

Faisal Humayun on InvestorPlace | March 17, 2023

COVID-19 pill Paxlovid moves closer to full FDA approval

Pfizer’s COVID-19 pill Paxlovid won another vote of confidence from U.S. health advisers Thursday, clearing the way for its full regulatory approval by the Food and Drug Administration. The medication has been used by millions of Americans since the FDA granted it emergency use authorization in late 2021. The agency has the final say on giving Pfizer's drug full approval and is expected to decide by May.

Yahoo | March 16, 2023

Read More 'PFE' Stories Here

PFE Price Returns

1-mo N/A
3-mo -20.54%
6-mo -6.11%
1-year -20.73%
3-year 65.05%
5-year 49.27%
YTD -19.92%
2022 -10.41%
2021 66.70%
2020 3.23%
2019 -6.91%
2018 24.82%

PFE Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full PFE Dividend History

Continue Researching PFE

Want to see what other sources are saying about Pfizer Inc's financials and stock price? Try the links below:

Pfizer Inc (PFE) Stock Price | Nasdaq
Pfizer Inc (PFE) Stock Quote, History and News - Yahoo Finance
Pfizer Inc (PFE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7242 seconds.